国际肿瘤学杂志

国际肿瘤学杂志 ›› 2022, Vol. 49 ›› Issue (1): 45-50.doi: 10.3760/cma.j.cn371439-20210106-00006

• 论著 • 上一篇    下一篇

晚期胃癌中miR-524-5p与SOX9表达的相关性及其对化疗疗效和预后的影响

罗丽云, 赖灿辉(), 梁仁佩, 杨爱武, 林志敏   

  1. 中国人民解放军联勤保障部队第九一〇医院肿瘤内科,泉州 362000
  • 收稿日期:2021-01-06 修回日期:2021-10-19 出版日期:2022-01-08 发布日期:2022-01-17
  • 通讯作者: 赖灿辉 E-mail:toby217@126.com

Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis

Luo Liyun, Lai Canhui(), Liang Renpei, Yang Aiwu, Lin Zhimin   

  1. Department of Oncology, 910th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Quanzhou 362000, China
  • Received:2021-01-06 Revised:2021-10-19 Online:2022-01-08 Published:2022-01-17
  • Contact: Lai Canhui E-mail:toby217@126.com

RichHTML

48

PDF

157

摘要：

目的 研究晚期胃癌中miR-524-5p与性别决定区Y框蛋白9(SOX9)表达的相关性及其对化疗疗效和预后的影响。方法 选择2015年1月至2017年12月在中国人民解放军联勤保障部队第九一〇医院诊断为晚期胃癌并接受DCF(多西他赛+顺铂+氟尿嘧啶)方案化疗的82例患者作为研究对象,采用荧光定量PCR法检测胃癌组织中miR-524-5p、SOX9的表达水平,分析miR-524-5p与SOX9表达的相关性,比较不同miR-524-5p、SOX9表达水平患者化疗总有效率,分析miR-524-5p联合SOX9对化疗疗效的预测价值,分析患者的总生存期(OS)及无进展生存期(PFS)。结果 miR-524-5p、SOX9的表达与晚期胃癌患者的性别、年龄无关(均P>0.05),与晚期胃癌患者的分化程度(χ2=3.577,P=0.001;χ2=5.654,P<0.001)、远处转移(χ2=2.466,P=0.016;χ2=5.218,P<0.001)有关。晚期胃癌中miR-524-5p与SOX9的表达呈负相关(r=-0.348,P=0.001)。根据胃癌组织miR-524-5p、SOX9表达中位数分为高表达与低表达患者,miR-524-5p≥0.64为高表达(n=41),<0.64为低表达(n=41);SOX9≥1.84为高表达(n=41),<1.84为低表达(n=41)。miR-524-5p高表达晚期胃癌患者的总有效率58.54%(24/41)高于miR-524-5p低表达患者的24.39%(10/41),差异有统计学意义(χ2=9.484,P=0.002);SOX9高表达晚期胃癌患者的总有效率21.95%(9/41),低于SOX9低表达患者的60.98%(25/41),差异有统计学意义(χ2=12.863,P<0.001)。受试者工作特征曲线分析显示,miR-524-5p和SOX9的表达对化疗疗效具有预测价值,曲线下面积分别为0.753(95%CI为0.6440.861,P<0.001)和0.660(95%CI为0.5400.780,P=0.014)。miR-524-5p联合SOX9对化疗疗效具有预测价值,曲线下面积为0.768(95%CI为0.6670.868,P<0.001)。miR-524-5p高表达晚期胃癌患者的中位PFS为8个月,中位OS为14个月,均长于miR-524-5p低表达患者(6个月、9个月),差异均有统计学意义(χ2=21.160,P<0.001;χ2=29.730,P<0.001);SOX9高表达晚期胃癌患者的中位PFS为7个月,中位OS为10个月,均短于SOX9低表达患者(8个月、12个月),差异均有统计学意义(χ2=6.345,P=0.012;χ2=4.107,P=0.043)。结论 晚期胃癌组织中miR-524-5p与SOX9的表达呈负相关,miR-524-5p高表达、SOX9低表达的患者化疗疗效及预后均优于miR-524-5p低表达、SOX9高表达的患者。

关键词: 胃肿瘤, 微RNAs, 药物疗法, 预后, SOX9

Abstract:

Objective To investigate the correlation between the expressions of miR-524-5p and sex determining region Y box protein 9 (SOX9) in advanced gastric cancer and their influences on the efficacy and prognosis of chemotherapy. Methods A total of 82 patients diagnosed as advanced gastric cancer who received DCF (docetaxel + cisplatin + fluorouracil) chemotherapy in 910th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army from January 2015 to December 2017 were selected as the research objects. The expression levels of miR-524-5p and SOX9 in gastric cancer tissues were detected by fluorescence quantitative PCR. The correlation between the expressions of miR-524-5p and SOX9 was analyzed, the total effective rates of chemotherapy in patients with different miR-524-5p and SOX9 expression levels were compared, and the predictive value of miR-524-5p combined with SOX9 on the efficacy of chemotherapy was analyzed. Overall survival (OS) and progression-free survival (PFS) were analyzed. Results The expressions of miR-524-5p and SOX9 were not related to gender or age of patients with advanced gastric cancer (all P>0.05), but were related to the degree of differentiation (χ2=3.577, P=0.001; χ2=5.654, P<0.001) and distant metastasis (χ2=2.466, P=0.016; χ2=5.218, P<0.001) of patients with advanced gastric cancer. There was a negative correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer (r=-0.348, P=0.001). According to the median expressions of miR-524-5p and SOX9 in gastric cancer tissues, patients were divided into high expression and low expression groups, miR-524-5p≥0.64 was high expression (n=41), <0.64 was low expression (n=41), SOX9≥1.84 was high expression (n=41), and <1.84 was low expression (n=41). The total effective rate of advanced gastric cancer patients with high expression of miR-524-5p was 58.54% (24/41), which was higher than that of patients with low expression of miR-524-5p (24.39%, 10/41), and there was a statistically significant difference (χ2=9.484, P=0.002). The total effective rate of advanced gastric cancer patients with high expression of SOX9 was 21.95% (9/41), which was lower than 60.97% (25/41) of patients with low expression of SOX9, and there was a statistically significant difference (χ2=12.863, P<0.001). Receiver operating characteristic curve analysis showed that the expressions of miR-524-5p and SOX9 had predictive value for the efficacy of chemotherapy, and the area under the curve was 0.753 (95%CI: 0.644-0.861, P<0.001) and 0.660 (95%CI: 0.540-0.780, P=0.014) respectively. The combination of miR-524-5p and SOX9 had predictive value for the efficacy of chemotherapy, and the area under the curve was 0.768 (95%CI: 0.667-0.868, P<0.001). The median PFS and OS of patients with high expression of miR-524-5p were 8 months and 14 months, which were longer than those of patients with low expression of miR-524-5p (6 months, 9 months), and there were statistically significant differences (χ2=21.160, P<0.001; χ2=29.730, P<0.001). The median PFS and OS of patients with high expression of SOX9 were 7 months and 10 months, which were shorter than those of patients with low expression of SOX9 (8 months, 12 months), and there were statistically significant differences (χ2=6.345, P=0.012; χ2=4.107, P=0.043). Conclusion There is a negative correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer tissues. The chemotherapy efficacy and prognosis of patients with high expression of miR-524-5p and low expression of SOX9 are better than those of patients with low expression of miR-524-5p and high expression of SOX9.

Key words: Stomach neoplasms, MicroRNAs, Drug therapy, Prognosis, SOX9